EIGRQ Projected Dividend Yield

Eiger BioPharmaceuticals Inc ( OTCBB : EIGRQ )

Eiger BioPharmaceuticals is a commercial-stage biopharmaceutical company. Co.'s portfolio includes a late-stage clinical development pipeline with five clinical product candidates and one U.S. Food and Drug Administration (FDA)-approved product. Co.'s clinical product candidates include: Lonafarnib for Hepatitis Delta Virus (HDV), Peginterferon Lambda for HDV, Combination Therapy for HDV; Peginterferon Lambda (lambda) for COVID-19, Avexitide in Congenital Hyperinsulinism, and Avexitide in Post-Bariatric Hypoglycemia. Co. has received FDA approval for Zokinvy to reduce the risk of mortality in Progeria and to treat processing-deficient Progeroid Laminopathies.

21 YEAR PERFORMANCE RESULTS